Seroprevalence of anti-SARS-CoV-2 IgG antibodies in resident physicians
Main Article Content
Keywords
Physicians, Antibodies, Viral, SARS Virus
Abstract
Background: COVID-19 pandemic spread around the world swiftly; there are several diagnostic strategies available. Health workers, especially medical residents (MR), are a high-risk population for acquiring this infection.
Objective: To estimate the seroprevalence of antibodies against SARS-CoV-2 and the associated factors in MR of a third level hospital.
Material and methods: 330 MR from different specialties were evaluated with a questionnaire and collection of blood samples for analysis by microparticle chemiluminescent immunoassay. The prevalence of previous infection was defined by seropositivity of these antibodies. Descriptive statistics and concordance between the RT-PCR tests and the presence of anti-SARS-CoV-2 IgG were used.
Results: Of 330 MR, 84.5% actively participated in COVID patient care. One out of 3 reported symptoms of COVID-19; in 67.6% the possible site of infection was a hospital setting not associated with the COVID area. Out of 71 symptomatic subjects, 61.9% underwent RT-PCR against SARS-CoV-2; 20 were positive. In 15.8% of the total, the presence of anti-SARS-CoV-2 IgG antibodies was determined. Only 1 out of 3 subjects with a positive PCR had antibodies, and 11.3% of the cases, even with a positive RT-PCR test, did not develop humoral immunity.
Conclusions: The seroprevalence was lower than that reported at the national level, potentially due to protection measures. The main risk factor was contact with the virus in areas of the hospital not related to COVID, making it imperative to reinforce security protocols in those spaces.
References
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang Q et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. doi: 10.1186/s40249-020-00646-x.
Sun J, He W, Wang L, Lai A, Ji X, Zhai X et al. COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives. Trends in Mol Med. 2020;26(5):483-95. doi: 10.1016/j.molmed.2020.02.008.
Secretaría de Salud. Coronavirus COVID-19 Comunicado Técnico Diario. México: Secretaría de Salud. Disponible en: https://www.gob.mx/salud/documentos/informe-tecnico-diario-covid19-2022.
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-6. doi: 10.1007/s12098-020-03263-6.
Wang W, Xu Y, Gao R, Lu R, Han K, Wu G et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;323(18):1843-4. doi: 10.1001/jama.2020.3786.
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-82. doi: 10.7326/M20-0504.
Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-9. doi: 10.1056/NEJMc2001737.
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8): 782-93. doi:10.1001/jama.2020.12839.
Lan F-Y, Filler R, Mathew S, Buley J, Iliaki E, Bruno-Murtha LA et al. COVID-19 symptoms predictive of healthcare workers’ SARS-CoV-2 PCR results. PLoS ONE 2020,15(6):e0235460. doi: 10.1371/journal.pone.0235460.
Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020;323(22):2249-51. doi: 10.1001/jama.2020.8259.
Zhou Y, Zhang L, Xie Y, Wu J. Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics. Lab Invest. 2022;102(1):4-13. doi: 10.1038/s41374-021-00663-w.
Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020;56(2):2000763. doi: 10.1183/13993003.00763-2020.
World Health Organization. Serology in the context of COVID-19. Geneva: WHO; [sin fecha de publicación]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/serology-in-the-context-of-covid-19.
Aguas R, Corder RM, King JG, Gonçalves G, Ferreira MU, Gomes MGM. Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics. MedRxiv. 2020. doi: 10.1101/2020.07.23.20160762.
Lisboa-Bastos M, Tavaziva G, Abidi SK, Campbell JR, Campbell LP, Johnston JC et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516. doi: 10.1136/bmj.m2516.
Loeffelholza M, Tangb Y. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect. 2020;9(1):747-56. doi: 10.1080/22221751.2020.1745095.
To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-74. doi: 10.1016/S1473-3099(20)30196-1.
Younes N, Al-Sadeq D, AL-Jighefee H, Younes S, Al-Jamal O, Daas HI et al. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses. 2020;12(6):582. doi: 10.3390/v12060582.
Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. MedRxiv. 2020;2020.04.14.20065771. doi: 10.1101/2020.04.14.20065771.
Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19: the case for health-care worker screening to prevent hospital transmission. Lancet. 2020;395(10234):1418-20. doi: 10.1016/S0140-6736(20)30917-X.
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-44. doi: 10.1016/S0140-6736(20)31483-5.
Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. doi: 10.1038/s41467-020-17318-x.
Muñoz-Medina JE, Grajales-Muñiz C, Salas-Lais AG, Fernandes-Matano L, López-Macías C, Monroy-Muñoz IE, et al. SARS-CoV-2 IgG antibodies seroprevalence and Sera neutralizing activity in MEXICO: A national cross-sectional study during 2020. Microorganisms. 2021;9(4):850. doi: 10.3390/microorganisms9040850.
Remes-Troche JM, Ramos-de la Medina A, Manríquez-Reyes M, Martínez-Pérez Maldonado L, Solis-Gonzalez MA, Hernández Flores KG, et al. Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico). MedRxiv. 2020. doi: 10.1101/2020.10.19.20215558.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.